Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 19 2023 - 8:00AM
Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that it has commenced development of a novel formulation as a
targeted prophylactic treatment, designated as SPC-15, intended for
stress, anxiety, and PTSD.
Development of the drug formulation is pursuant to the Company’s
sponsored research agreement with Columbia University. Preclinical
studies in the field suggest that SPC-15 could be a promising
therapeutic target for the treatment of cognitive impairment, PTSD,
and stress-related disorders.
“We are advancing our development of SPC-15 through this
formulation and feasibility study investigating dose strengths and
delivery,” said Eric Weisblum, Chief Executive Officer of Silo
Pharma. “The SPC-15 treatment protocol predicts levels of
severity or progression of stress-related disorders and their
metabolomic biomarkers’ response to pharmacological treatments.
Based on our own research to date coupled with published
preclinical data, we believe SPC-15 could have a profound impact on
treating stress and anxiety disorders including PTSD, we will
further use this data to help us with our upcoming studies related
to SPC-14 Alzheimer’s asset.”
Targeted by SPC-15, anxiety, PTSD, and other stress-related
disorders are becoming more frequent in Americans aged 18+.
According to the World Health Organization in 2019, 300+ million
people were living with an anxiety disorder, and according to the
National Center for PTSD, around 12 million adults in the U.S.
alone are reported to have PTSD., According to Fortune Business
Insights, the global treatment market size for anxiety disorders
and depression is projected to reach $13.0 billion in 2027.
Silo Pharma was recently granted a U.S. patent covering SPC-15
as a method for the treatment and prevention of stress-induced
affective disorders in females.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact 800-705-0120 investors@silopharma.com
World Health Organization; Mental disorders. June 2022.U.S.
Department of Veterans Affairs, PTSD: National Center for PTSD; How
Common Is PTSD in Adults?
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Jul 2023 to Jul 2024